WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563277

CAS#: 862250-23-5

Description: FCPT is an ATP competitive inhibitor of kinesin-5.

Chemical Structure

CAS# 862250-23-5

Theoretical Analysis

MedKoo Cat#: 563277
Name: FCPT
CAS#: 862250-23-5
Chemical Formula: C17H13FN2S
Exact Mass: 296.0783
Molecular Weight: 296.36
Elemental Analysis: C, 68.90; H, 4.42; F, 6.41; N, 9.45; S, 10.82

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: FCPT;

IUPAC/Chemical Name: 2-(1-(4-Fluorophenyl)cyclopropyl)-4-(pyridin-4-yl)thiazole


InChi Code: InChI=1S/C17H13FN2S/c18-14-3-1-13(2-4-14)17(7-8-17)16-20-15(11-21-16)12-5-9-19-10-6-12/h1-6,9-11H,7-8H2

SMILES Code: FC1=CC=C(C2(C3=NC(C4=CC=NC=C4)=CS3)CC2)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 296.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Hattenbach LO, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N, Lang GE, Rehak M, Taylor SR, Wolf A, Weiss C, Paulus EM, Pielen A, Hoerauf H; COMRADE-B Study Group. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol. 2018 Feb;96(1):e10-e18. doi: 10.1111/aos.13381. Epub 2017 Mar 2. PubMed PMID: 28251811.

2: Dyakova ME. Features purine metabolism in patients with pulmonary tuberculosis. Patol Fiziol Eksp Ter. 2016 Jul-Sep;60(3):36-41. PubMed PMID: 29244467.

3: Dong N, Xu B, Wang B, Chu L, Tang X. Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery. Biomed Res Int. 2015;2015:126984. doi: 10.1155/2015/126984. Epub 2015 Feb 25. PubMed PMID: 25811020; PubMed Central PMCID: PMC4355626.

4: Alm S, Olsen SO, Honkanen P. The role of family communication and parents' feeding practices in children's food preferences. Appetite. 2015 Jun;89:112-21. doi: 10.1016/j.appet.2015.02.002. Epub 2015 Feb 7. PubMed PMID: 25666300.

5: Chu L, Wang B, Xu B, Dong N. Aqueous cytokines as predictors of macular edema in non-diabetic patients following uncomplicated phacoemulsification cataract surgery. Mol Vis. 2013 Nov 24;19:2418-25. eCollection 2013. PubMed PMID: 24319335; PubMed Central PMCID: PMC3850971.

6: Collins E, Mann BJ, Wadsworth P. Eg5 restricts anaphase B spindle elongation in mammalian cells. Cytoskeleton (Hoboken). 2014 Feb;71(2):136-44. doi: 10.1002/cm.21158. Epub 2013 Dec 12. PubMed PMID: 24285623; PubMed Central PMCID: PMC5397254.

7: Titarenko OT, D'iakova ME, Ésmedliaeva DS, Pavlova MV, El'kin AV, Alekseeva NP, Bondarenko BB. [Peculiarities of the circulating phagocytes functional activity in patients with different forms of drug-resistant pulmonary tuberculosis]. Biomed Khim. 2012 Jul-Aug;58(4):467-74. Russian. PubMed PMID: 23413691.

8: Hommer A. [Combination therapy in the medical treatment of glaucoma]. Klin Monbl Augenheilkd. 2013 Feb;230(2):133-40. doi: 10.1055/s-0032-1328095. Epub 2013 Jan 20. German. PubMed PMID: 23335083.

9: Groen AC, Needleman D, Brangwynne C, Gradinaru C, Fowler B, Mazitschek R, Mitchison TJ. A novel small-molecule inhibitor reveals a possible role of kinesin-5 in anastral spindle-pole assembly. J Cell Sci. 2008 Jul 15;121(Pt 14):2293-300. doi: 10.1242/jcs.024018. Epub 2008 Jun 17. PubMed PMID: 18559893; PubMed Central PMCID: PMC2902979.

10: Shmelev EI, Kuklina GM, Kalinina EE. [Treatment of bronchial obstruction in patients with pulmonary tuberculosis]. Probl Tuberk Bolezn Legk. 2004;(8):57-61. Russian. PubMed PMID: 15478563.

11: Erokhin VV, Gedymin LE, Zemskova S, Lepekha LN, Podolianko PN. [Features of morphological reactions in caseous pneumonia]. Probl Tuberk. 2001;(7):50-5. Russian. PubMed PMID: 11763566.

12: Kakizoe S, Kakizoe Y, Kakizoe S. [Frequent chemolipiodolization and prostaglandin E1 administration for hepatocellular carcinoma with advanced liver cirrhosis]. Nihon Shokakibyo Gakkai Zasshi. 1998 Apr;95(4):311-6. Japanese. PubMed PMID: 9591406.